BCAN, brevican, 63827

N. diseases: 25; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0017638
Disease: Glioma
Glioma
0.280 Biomarker disease BEFREE This work demonstrates that BCAN-NTRK1 is a bona fide human glioma driver and describes a general strategy to define the oncogenic potential of novel glioma-associated genomic rearrangements and to generate accurate preclinical models of this lethal human cancer. 28695888 2017
CUI: C0017638
Disease: Glioma
Glioma
0.280 AlteredExpression disease BEFREE Brain Enriched Hyaluronan Binding (BEHAB)/brevican (B/b), is a CNS-specific ECM constituent and is upregulated in the glioma TME. 25052349 2014
CUI: C0017638
Disease: Glioma
Glioma
0.280 Biomarker disease BEFREE Surprisingly, HAPLN4 increased glioma cell adhesion and migration and even potentiated the motogenic effect of brevican. 19633295 2009
CUI: C0017638
Disease: Glioma
Glioma
0.280 Biomarker disease LHGDN Moreover, the N-terminal cleavage product of brevican, but not the full-length protein, associates with fibronectin in cultured cells and in surgical samples of glioma. 18611854 2008
CUI: C0017638
Disease: Glioma
Glioma
0.280 Biomarker disease BEFREE Moreover, the N-terminal cleavage product of brevican, but not the full-length protein, associates with fibronectin in cultured cells and in surgical samples of glioma. 18611854 2008
CUI: C0017638
Disease: Glioma
Glioma
0.280 AlteredExpression disease LHGDN These results demonstrate for the first time that ADAMTS-5 is capable of degrading brevican and is overexpressed in glioblastoma cells, and suggest that ADAMTS-5 may play a role in glioma cell invasion through the cleavage of brevican. 16133547 2005
CUI: C0017638
Disease: Glioma
Glioma
0.280 Biomarker disease BEFREE These results demonstrate for the first time that ADAMTS-5 is capable of degrading brevican and is overexpressed in glioblastoma cells, and suggest that ADAMTS-5 may play a role in glioma cell invasion through the cleavage of brevican. 16133547 2005
CUI: C0017638
Disease: Glioma
Glioma
0.280 Biomarker disease RGD In addition, B/b130 is the major isoform of BEHAB/brevican that is up-regulated in a rat model of invasive glioma and may therefore contribute to the invasive ability of glioma cells. 12799382 2003
CUI: C0017638
Disease: Glioma
Glioma
0.280 ModifyingMutation disease RGD It will be important to investigate the effect of inhibiting cleavage of BEHAB/brevican in these cells and to determine the therapeutic potential of inhibiting BEHAB/brevican cleavage in gliomas. 11585735 2001
CUI: C0017638
Disease: Glioma
Glioma
0.280 Biomarker disease BEFREE The distinct patterns of regulation of expression of the two isoforms suggest distinct mechanisms of regulation of BEHAB/brevican during development and in glioma. 11054543 2000
CUI: C0017638
Disease: Glioma
Glioma
0.280 AlteredExpression disease BEFREE BEHAB/brevican mRNA is expressed in the ventricular zone coincident with the initial proliferation and migration of glial cells and in surgical samples of human glioma, where glial-derived cells proliferate and migrate. 10364444 1999
CUI: C0017638
Disease: Glioma
Glioma
0.280 Biomarker disease BEFREE The noninvasive 9L glioma cell was transfected with either full-length BEHAB/brevican or the HABD and tested for invasion in in vitro and in vivo invasion assays. 9502798 1998
CUI: C0555198
Disease: Malignant Glioma
Malignant Glioma
0.210 Biomarker disease BEFREE Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. 16061654 2005
CUI: C0555198
Disease: Malignant Glioma
Malignant Glioma
0.210 Biomarker disease RGD A novel membrane-associated glycovariant of BEHAB/brevican is up-regulated during rat brain development and in a rat model of invasive glioma. 12799382 2003
CUI: C0555198
Disease: Malignant Glioma
Malignant Glioma
0.210 ModifyingMutation disease RGD Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats. 11585735 2001
CUI: C0740392
Disease: Infarction, Middle Cerebral Artery
Infarction, Middle Cerebral Artery
0.200 Biomarker disease RGD Growth-associated gene expression after stroke: evidence for a growth-promoting region in peri-infarct cortex. 15869933 2005
CUI: C0752308
Disease: Hypoxia-Ischemia, Brain
Hypoxia-Ischemia, Brain
0.200 Biomarker disease RGD The effect of hypoxic-ischemic brain injury in perinatal rats on the abundance and proteolysis of brevican and NG2. 15817274 2005
CUI: C2985280
Disease: Blood Protein Measurement
Blood Protein Measurement
0.100 GeneticVariation phenotype GWASCAT Genomic atlas of the human plasma proteome. 29875488 2018
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.030 Biomarker phenotype BEFREE These results demonstrate for the first time that ADAMTS-5 is capable of degrading brevican and is overexpressed in glioblastoma cells, and suggest that ADAMTS-5 may play a role in glioma cell invasion through the cleavage of brevican. 16133547 2005
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.030 Biomarker phenotype BEFREE Cleavage of the BEHAB/brevican protein may increase invasion of tumor cells. 9811619 1998
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.030 Biomarker phenotype BEFREE The noninvasive 9L glioma cell was transfected with either full-length BEHAB/brevican or the HABD and tested for invasion in in vitro and in vivo invasion assays. 9502798 1998
CUI: C0028945
Disease: oligodendroglioma
oligodendroglioma
0.020 AlteredExpression disease BEFREE We report that the BCAN, CSPG4, IGF2BP3, PTPRZ1 and TNC proteins are significantly over-expressed at the mRNA (n = 159) and protein (n = 36) levels in grade II/III glioma patients as compared to non-tumor samples (IGF2BP3 being absent from oligodendroglioma). 29308320 2018
Well Differentiated Oligodendroglioma
0.020 AlteredExpression disease BEFREE We report that the BCAN, CSPG4, IGF2BP3, PTPRZ1 and TNC proteins are significantly over-expressed at the mRNA (n = 159) and protein (n = 36) levels in grade II/III glioma patients as compared to non-tumor samples (IGF2BP3 being absent from oligodendroglioma). 29308320 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.020 Biomarker disease BEFREE It is possible that lecticans, particularly brevican, inhibit synaptic plasticity in this model of AD. 26337292 2015
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.020 Biomarker disease BEFREE As proteoglycans stabilize synaptic structure and inhibit molecular plasticity, defective brevican processing observed in Abeta-bearing mice and potentially end-stage human AD, may contribute to deficient neural plasticity. 20180882 2010